NOCIL

- NOCIL Limited granted 1,04,960 Performance Restricted Stock Units (PRSUs) under its Long Term Incentive Plan 2024 on 23rd September 2026. - The exercise price is ₹10 per share. - PRSUs vest in three years and can be exercised from five years after the grant date.

- NOCIL Limited announced the closure of its trading window for Designated Persons from September 30, 2026. - This is ahead of the Unaudited Financial Results for the quarter and half-year ended September 30, 2026. - The window will reopen 48 hours after the results declaration.

- Concall Schedule - Concall Date: 28th September 2026 - Concall Time: 02:00 pm onwards

- NOCIL received queries from NSE and BSE on September 9, 2026, regarding a spurt in trading volume. - The company clarified there is no undisclosed price-sensitive information and is compliant with SEBI (LODR) Regulations.

- NOCIL Limited announced the appointment of M/s Deloitte Haskins & Sells Chartered Accountants LLP as Statutory Auditors for a five-year term. - The term commences from the conclusion of the 65th Annual General Meeting (July-Aug 2027) until the 70th Annual General Meeting (FY 2031-32). - The appointment is subject to the approval of the members at the 65th AGM. - M/s Kalyaniwalla & Mistry LLP will continue as auditors until the 65th AGM, completing their second consecutive term.

- Q1 FY27 Consolidated Revenue from Operations ₹403 Cr (▲20% YoY) - Q1 FY27 Consolidated EBITDA ₹45 Cr (▲48% YoY), with EBITDA margin of 11.2% (▲210 bps YoY) - Q1 FY27 Consolidated PAT ₹28 Cr (▲61% YoY) - Volumes grew 9% YoY, though experienced a 3% sequential decline due to temporary supply-side and logistics issues. - FY27 revenue guidance is ₹1,400-₹1,600 Cr with an EBITDA in the region of 10%. - Anti-dumping duty approved on Sulphonamides (CBS and NS); positive recommendation for Pilflex 13 awaited government approval. - New TDQ plant trial production progressing well, with revenues expected from Q4 FY27. - Overall demand outlook for the tyre industry remains positive, despite near-term seasonal moderation.

- The audio recording of the Investors / Analyst conference call on the operational and financial performance for the quarter ended June 30, 2026, has been uploaded to NOCIL Limited's website. - The recording is accessible via the provided link.

- Consolidated Revenue ₹403Cr vs ₹335.83Cr (▲20% YoY) - EBITDA ₹45.14Cr vs ₹30.56Cr (▲47.7% YoY) - PAT ₹28Cr vs ₹17.39Cr (▲61% YoY) - EBITDA Margin 11.2% vs 9.1% (▲210bps)

- The 64th Annual General Meeting (AGM) of NOCIL Limited was held on August 3, 2026. - Members adopted the audited financial statements for the year ended March 31, 2026. - A dividend of Rs. 1.50/- per equity share was declared. - Re-appointments of directors and Executive Chairman, and appointments of new Independent Directors were approved.

- Members/Shareholders approved appointments and re-appointments of Directors at the 64th AGM held on 3rd August 2026. - Mr. Sanjiv Lal and Mr. Sabyaschi Patnaik appointed as Independent Directors for 5 years (7th May 2026 to 6th May 2031). - Mr. Hrishikesh A. Mafatlal re-appointed as Executive Chairman for 5 years (19th August 2026 to 18th August 2031). - The company affirmed that the appointed directors are not debarred by SEBI.

- The 64th Annual General Meeting (AGM) of NOCIL Limited was held on August 3, 2026. - All 7 resolutions proposed at the AGM were approved by the shareholders with an overwhelming majority. - Key approvals include the adoption of financial statements, declaration of a dividend on equity shares for FY26, re-appointment of Directors, and appointment of Independent Directors.

- Consolidated Revenue ₹403.02Cr vs ₹336.22Cr (▲19.87% YoY) - EBITDA ₹45.22Cr vs ₹30.58Cr (▲47.87% YoY) - PAT ₹27.76Cr vs ₹17.26Cr (▲60.83% YoY) - EBITDA Margin 11.22% vs 9.09% (▲213bps)